668 related articles for article (PubMed ID: 19778669)
1. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
Menown I; Montalescot G; Pal N; Fidler C; Orme M; Gillard S
Adv Ther; 2010 Mar; 27(3):181-91. PubMed ID: 20422473
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
4. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
[TBL] [Abstract][Full Text] [Related]
7. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
Gabriel RS; White HD
Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):851-7. PubMed ID: 17867915
[TBL] [Abstract][Full Text] [Related]
8. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.
Fox KA; Antman EM; Montalescot G; Agewall S; SomaRaju B; Verheugt FW; Lopez-Sendon J; Hod H; Murphy SA; Braunwald E
J Am Coll Cardiol; 2007 Jun; 49(23):2249-55. PubMed ID: 17560289
[TBL] [Abstract][Full Text] [Related]
9. Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial.
Steinberg BA; Moghbeli N; Buros J; Ruda M; Parkhomenko A; Raju BS; García-Castillo A; Janion M; Nicolau JC; Fox KA; Morrow DA; Gibson CM; Antman EM
Am Heart J; 2007 Jul; 154(1):54-61. PubMed ID: 17584551
[TBL] [Abstract][Full Text] [Related]
10. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial.
Aasa M; Henriksson M; Dellborg M; Grip L; Herlitz J; Levin LA; Svensson L; Janzon M
Am Heart J; 2010 Aug; 160(2):322-8. PubMed ID: 20691839
[TBL] [Abstract][Full Text] [Related]
11. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).
Antman EM; Morrow DA; McCabe CH; Jiang F; White HD; Fox KA; Sharma D; Chew P; Braunwald E;
Am Heart J; 2005 Feb; 149(2):217-26. PubMed ID: 15846258
[No Abstract] [Full Text] [Related]
12. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
De Luca G; Marino P
Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
[TBL] [Abstract][Full Text] [Related]
13. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
Scirica BM; Morrow DA; Sadowski Z; Ruda M; Nicolau JC; Giugliano RP; Wiviott SD; Sabatine MS; Shui A; Antman EM; Braunwald E
Eur Heart J; 2007 Sep; 28(17):2070-6. PubMed ID: 17600039
[TBL] [Abstract][Full Text] [Related]
14. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
Morrow DA; Antman EM; Fox KA; White HD; Giugliano R; Murphy SA; McCabe CH; Braunwald E;
Eur Heart J; 2010 Sep; 31(17):2097-102. PubMed ID: 20400762
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial.
Welsh RC; Sauriol L; Zhang Z; Kolm P; Weintraub WS; Theroux P
Can J Cardiol; 2009 Dec; 25(12):e399-405. PubMed ID: 19960133
[TBL] [Abstract][Full Text] [Related]
16. TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction.
Ruff CT; Wiviott SD; Morrow DA; Mohanavelu S; Murphy SA; Antman EM; Braunwald E;
Am J Med; 2007 Nov; 120(11):993-8. PubMed ID: 17976428
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.
Gibler KB; Huskamp HA; Sabatine MS; Murphy SA; Cohen DJ; Cannon CP
Crit Pathw Cardiol; 2010 Mar; 9(1):14-8. PubMed ID: 20215905
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
